Cingulate to Host CNS Key Opinion Leader Panel in New York City
Cingulate to Host CNS Key Opinion Leader Panel in New York City
Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR Drug Delivery Platform Innovations
Cingulate、其 3 期注意力缺陷多動障礙成人數據、焦慮和 PTR 藥物遞送平台創新的專家分析
KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it will be hosting a key opinion leader event on the morning of October 23, 2023, at the Union League Club in New York City.
堪薩斯州堪薩斯城，2023年10月17日（GLOBE NEWSWIRE）— cingulate Inc. （納斯達克：CING）是一家利用其專有的 Precision Timed Release (PTR) 藥物遞送平台技術來建立和推進下一代藥品管道的生物製藥公司今天宣佈，它將在當天上午舉辦一場重要的意見領袖活動 2023年10月23日，在紐約市的聯盟聯賽俱樂部舉行。
The live-streamed event will be held from 10:00am-11:30am EST at the Union League Club in Midtown Manhattan, and will focus on the Company's leading, late-stage asset CTx-1301(dexmethylphenidate), along with ADHD and anxiety-related disorders. For those in the New York area who would like to attend, there will be space for approximately 25-30 guests in the club's Grant Room. Those who wish to watch the event virtually may do so through the link provided here, with the passcode 429018.
直播活動將於美國東部標準時間上午10點至上午11點30分在曼哈頓中城的聯合聯賽俱樂部舉行，重點是公司領先的後期資產CTX-1301（哌醋甲酯）以及注意力缺陷多動障礙和焦慮相關疾病。對於那些想參加的紐約地區人士，俱樂部的Grant Room將爲大約25-30位客人提供空間。那些希望以虛擬方式觀看活動的人可以通過提供的鏈接進行觀看 這裏，使用密碼 429018。
What: Cingulate Key Opinion Leader Panel
什麼： Cingulate 關鍵意見領袖小組
Where: Union League Club (Grant Room)
39 East 37th Street, New York, NY 10016
在哪裏： 聯盟聯賽俱樂部（Grant Room）
39 East 37第四 Street，紐約，紐約，10016
When: Monday October 23, 2023, 10am-11:30am EST
什麼時候： 美國東部標準時間2023年10月23日星期一上午10點至上午11點30分
Attire: The Union League Club requests that in-person attendees abide by club dress guidelines. For more information, please visit the club's website.
服裝： 聯盟聯賽俱樂部要求面對面出席者遵守俱樂部着裝指南。欲了解更多信息，請訪問俱樂部的 網站。
The event may be added to calendars through the following links:
Add to Calendar
Add to Google Calendar
可以通過以下鏈接將該活動添加到日曆中：
添加到日曆
添加到谷歌日曆
Cingulate's Chief Medical Officer, Matthew Brams, M.D., and Chief Science Officer, Raul Silva, M.D., will moderate the discussion.
Cingulate的首席醫學官、醫學博士馬修·布拉姆斯和首席科學官勞爾·席爾瓦醫學博士將主持討論。
The panel will include Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator of Cingulate's recently completed Phase 3 adult dose-optimization study, as well as Greg Mattingly, M.D., Founding Partner, St. Charles Psychiatric Associates.
該小組將包括安·柴爾德雷斯醫學博士、精神病學和行爲醫學中心總裁、Cingulate最近完成的3期成人劑量優化研究的首席研究員，以及聖查爾斯精神病學協會創始合夥人格雷格·馬汀利醫學博士。
"The Cingulate team thanks Dr. Childress and Dr. Mattingly for their participation in this event. We believe this will be an excellent opportunity for healthcare providers, patients, advocacy groups, and the investor community to hear the Cingulate story and take a deeper look at our most recent Phase 3 data with two of the top key opinion leaders in ADHD and CNS disorders," said Cingulate Chairman & CEO Shane J. Schaffer.
“Cingulate 團隊感謝 Childress 博士和 Mattingly 博士參與本次活動。我們相信，對於醫療保健提供者、患者、倡導團體和投資者群體來說，這將是一個絕佳的機會，可以聽到Cingulate的故事，並與注意力缺陷多動障礙和中樞神經系統疾病領域的兩位頂級關鍵意見領袖一起更深入地了解我們最新的第三階段數據，” Cingulate董事長兼首席執行官Shane J. Schaffer說。
About Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD is a chronic neurobiological and developmental disorder that affects millions of children often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., approximately 6.4 million children and adolescents (11 percent) aged under the age of 18 have been diagnosed with ADHD. Among this group, approximately 80 percent receive treatment, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), almost double the size of the child and adolescent segment combined, however, only an estimated 20 percent receive treatment.
關於注意力缺陷/多動障礙（ADHD）
注意力缺陷多動障礙是一種慢性神經生物學和發育障礙，影響數百萬兒童，通常持續到成年。這種疾病的特點是持續的注意力不集中和/或多動衝動模式，干擾功能或發育。在美國，大約有640萬名18歲以下的兒童和青少年（11％）被診斷出患有注意力缺陷多動障礙。在該群體中，約有80％的人接受治療，65-90％的患者表現出持續到成年的臨床注意力缺陷多動障礙症狀。據估計，成人注意力缺陷多動障礙患病率約爲1100萬患者（4.4％），幾乎是兒童和青少年群體總規模的兩倍，但是，估計只有20％的人接受了治療。
About Anxiety
Anxiety disorders are the most common mental health concern in the U.S.1 Anxiety is the feeling of fear that occurs when faced with threatening or stressful situations or can be endogenous and not have an identified stressor. It can be a normal response when confronted with danger, but, if severe and chronic and affects functioning, it could be regarded as an anxiety disorder. An estimated 31 percent of U.S. adults experience an anxiety disorder at some time in their lives.2 People may live with anxiety for years before they are diagnosed or treated. The global COVID-19 crisis has exacerbated the diagnosis and treatment of anxiety and anxiety related disorders and as a result is a priority within the class of unmet medical needs in mental health.
關於焦慮
焦慮症是美國最常見的心理健康問題。1 焦慮是面對威脅或壓力大的情況時發生的恐懼感，或者可能是內源性的，沒有確定的壓力源。面對危險時，這可能是正常的反應，但是，如果嚴重和慢性並影響功能，則可能被視爲焦慮症。據估計，有31％的美國成年人在生命中的某個時候患有焦慮症。2 人們在被診斷或治療之前可能會在焦慮中生活多年。全球 COVID-19 危機加劇了焦慮和焦慮相關疾病的診斷和治療，因此成爲心理健康領域未得到滿足的醫療需求類別中的優先事項。
About CTx-1301
Cingulate's lead candidate, CTx-1301, utilizes Cingulate's proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold-standard of ADHD treatment due to their efficacy and safety, the long-standing challenge continues to be providing patients entire active-day duration of action. CTx-1301 is designed to precisely deliver three releases of medication at the predefined time, ratio, and style of release to optimize patient care in one tablet. The result is a rapid onset and entire active-day efficacy, with the third dose being released around the time when other extended-release stimulant products begin to wear off.
關於 ctx-1301
Cingulate的主要候選藥物CTX-1301利用Cingulate專有的PTR藥物遞送平台爲活性藥物成分哌醋甲酯創造了突破性的多核配方，該化合物已獲得美國食品藥品管理局批准用於治療注意力缺陷多動障礙。哌醋甲酯是興奮劑類藥物的一部分，它會增加大腦中的去甲腎上腺素和多巴胺活性，從而影響注意力和行爲。儘管興奮劑因其有效性和安全性而成爲注意力缺陷多動障礙治療的黃金標準，但長期存在的挑戰仍然是爲患者提供完整的活動日療程。CTX-1301旨在以預定義的發佈時間、比例和方式精確提供三次藥物釋放，從而在一片藥片中優化患者護理。結果是起效迅速，活性日療效良好，第三劑是在其他緩釋興奮劑產品開始消失的時候釋放的。
About Precision Timed Release (PTR) Platform Technology
Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate's innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, Oralogik, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD where one or more active pharmaceutical ingredients need to be delivered several times a day at specific, predefined time intervals and released in a manner that would offer significant improvement over existing therapies. To see Cingulate's PTR Platform click here.
關於精準定時發佈 (PTR) 平台技術
Cingulate正在開發注意力缺陷多動障礙和焦慮症候選產品，這些產品能夠使用Cingulate的創新PTR給藥平台技術實現真正的每日一次給藥。它包含專有的侵蝕屏障層（EBL），可在預先設定的精確時間控制藥物釋放，並且在預定釋放之前不會釋放藥物。EBL 技術被包裹在含藥物的核心周圍，形成片劑劑型。它旨在以受控的速度侵蝕，直到藥物最終從核心片劑中釋放出來。EBL 配方 Oralogik 已獲得 BDD Pharma 的許可。Cingulate打算利用其PTR技術來擴大和擴大其臨床階段的產品線，方法是識別和開發除焦慮症和注意力缺陷多動障礙以外的其他治療領域的其他候選產品，在焦慮和注意力缺陷多動障礙中，一種或多種活性藥物成分每天需要按特定的預定義時間間隔多次交付，並以比現有療法有顯著改進的方式發佈。要查看 Cingulate 的 PTR 平台，請點擊 這裏。
About Cingulate Inc.
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.
關於 Cingulate Inc.
Cingulate Inc.（納斯達克股票代碼：CING）是一家生物製藥公司，利用其專有的PTR藥物遞送平台技術來建立和推進下一代藥物產品線，旨在改善患有經常診斷的疾病的患者的生活，這些疾病的特徵是繁瑣的日常給藥方案和不理想的治療結果。Cingulate最初的重點是注意力缺陷多動障礙的治療，正在確定和評估其他治療領域，在這些領域，PTR技術可用於開發未來的候選產品，包括治療焦慮症。Cingulate 總部位於堪薩斯城。欲了解更多信息，請訪問 cingulate.com。
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC on March 10, 2023. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
前瞻性陳述
本新聞稿包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的 “前瞻性陳述”。這些前瞻性陳述包括除歷史事實陳述以外的所有陳述，涉及我們當前對未來業務事件的看法和假設，包括與我們的計劃、假設、預期、信念和目標有關的陳述，以及與產品開發、臨床研究、臨床和監管時間表、市場機會、競爭地位、業務戰略、潛在增長機會有關的陳述以及其他本質上具有預測性的陳述。這些陳述通常通過使用 “可能”、“可能”、“應該”、“將”、“相信”、“預期”、“預測”、“估計”、“預期”、“打算”、“計劃”、“繼續”、“展望”、“將”、“潛在” 等詞語來識別，以及具有未來或前瞻性質的類似陳述。提醒讀者，我們或代表我們提供的任何前瞻性信息都不能保證未來的表現。由於我們在向美國證券交易委員會（SEC）提交的文件中披露了各種因素，包括我們在2023年3月10日向美國證券交易委員會（SEC）提交的10-K表年度報告中的 “風險因素” 部分，實際業績可能與這些前瞻性陳述中包含的結果存在重大差異。所有前瞻性陳述僅代表其發表之日，除非法律要求，否則我們沒有義務更新或修改任何前瞻性陳述，無論是由於新信息、未來事件還是其他原因。
Investor Relations:
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
tdalton@cingulate.com
(913) 942-2301
投資者關係：
托馬斯·道爾頓
Cingulate 投資者與公共關係副總裁
tdalton@cingulate.com
(913) 942-2301
Matt Kreps
Darrow Associates
mkreps@darrowir.com
(214) 597-8200
馬特·克雷普斯
達羅合夥人
mkreps@darrowir.com
(214) 597-8200
Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com
(201) 723-5805
媒體關係
梅麗莎·韋布爾
Elixir Health 公共關係
mweible@elixirhealthpr.com
(201) 723-5805
譯文內容由第三人軟體翻譯。